Piper Sandler analyst David Westenberg maintained a Hold rating on Idexx Laboratories (IDXX – Research Report) today and set a price target of ...

Piper Sandler raised the firm’s price target on Idexx Laboratories (IDXX) to $510 from $435 and keeps a Neutral rating on the shares. The firm ...

Key Takeaways IDEXX Laboratories exceeded earnings and revenue estimates on sales of its animal testing products and price ...

IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

Idexx Laboratories stock was rising sharply Monday, even as the S&P 500 and major indexes remained in the red. The Dow Jones ...

IDEXX (IDXX) stock jumped 12% in early trading Monday after the pet healthcare company issued a Q4 earnings report and 2025 ...

Equities research analysts at William Blair decreased their Q1 2025 earnings per share estimates for shares of IDEXX ...

Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.

Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4 ...

Shares of IDEXX Laboratories Inc. IDXX slipped 1.71% to $460.56 Thursday, on what proved to be an all-around mixed trading ...

Spire Wealth Management trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 86.8% ...

IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to ...